Clinical Trials on Influenza Virus

Total 23547 results

Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Seasonal Influenza

Italy
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Ology Bioservices

Completed

Yearly Strain Variation Study, 2009/2010

Influenza | Seasonal Influenza

Austria
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
University of British Columbia
PHAC/CIHR Influenza Research Network

Completed

Comparison of 4 Influenza Vaccines in Seniors (PCIRNRT09)

Influenza Vaccine

Canada
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Columbia University

Completed

Adult Influenza Vaccination Text Message Reminders

Influenza Vaccination

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above

Human Influenza

Germany
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Influenza (Pandemic)

United States
Novavax

Completed

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Pandemic Influenza

United States
International Centre for Infectious Diseases, Canada
GlaxoSmithKline

Unknown

H1N1 Vaccine Safety in Manitoba, Canada

H1N1 Influenza

Canada
Hualan Biological Engineering, Inc.

Completed

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

Human Influenza

China
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B (PIPET B)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza (PIPET C)

Pandemic Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Seasonal Influenza

Germany
Abbott Biologicals
Quintiles, Inc.

Completed

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Influenza Vaccines

Czech Republic, Estonia, Lithuania
Dalhousie University
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); IWK Health Centre

Completed

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Seasonal Influenza

Canada
The University of Hong Kong

Completed

Convalescent Plasma Treatment in Severe 2009 H1N1 Infection

Influenza A

China
Seoul National University Hospital

Unknown

The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A

H1N1 Influenza

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Orakine Ltd, Dublin, Ireland

Terminated

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer (GP-INFA)

Influenza Infection

France
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

Influenza Disease

Italy
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Influenza (Healthy Volunteers)

Korea, Republic of
Hvivo
Pfizer

Completed

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

Influenza A H1N1

United Kingdom
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
Insight Therapeutics, LLC
Brown University; Genentech, Inc.; Case Western Reserve University

Active, not recruiting

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Influenza | Influenza, Human | Influenza -Like Illness

United States
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
University of Leicester
Sanofi Pasteur, a Sanofi Company; University Hospitals, Leicester; World Health... and other collaborators

Completed

Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness (BELIEVE)

Influenza | Influenza -Like Illness

United Kingdom
University of Athens
Hellenic Pasteur Institute

Completed

Influenza Vaccine Effectiveness of a Quadrivalent Vaccine in Pregnant Women and Young Infants, 2019-2020

Influenza in Human

Greece
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
China Academy of Chinese Medical Sciences
Renmin Hospital of Wuhan University; Children's Hospital of Soochow University and other collaborators

Unknown

Clinical Study of Reduning Injection for the Treatment of Influenza in Children

Influenza in Children
Public Health England

Completed

Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls (Flushed)

Influenza | Vaccination | Influenza Vaccination

United Kingdom
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
Pantec Biosolutions AG
Medical University of Vienna

Completed

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

Influenza in Human

Austria
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
David Scheifele
Canadian Institutes of Health Research (CIHR); PHAC/CIHR Influenza Research...

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults

H1N1/2009 Influenza

Canada
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Germany
University of Nottingham

Completed

Virus Shedding and Environmental Deposition of a Novel Influenza Virus

Novel (H1N1) Influenza

United Kingdom
Assistance Publique - Hôpitaux de Paris

Completed

Face Masks for Preventing Influenza Transmission (GRIPMASK)

Influenza Human

France
Seattle Children's Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

Inactivated Influenza Vaccine

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Prevention | Pandemic Influenza
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Pandemic Influenza Disease

Italy
The University of Hong Kong

Completed

Direct and Indirect Benefits of Influenza Vaccination in Schools and Households

Acute Respiratory Infection | Influenza-like Illness | Influenza Virus Infection

Hong Kong
National Taiwan University Hospital

Unknown

Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza Virus

Enterovirus 71 and Influenza Virus

Taiwan
MedImmune LLC
AstraZeneca

Suspended

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age (ICICLE)

Influenza Vaccine Effectiveness

United States, United Kingdom
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Prevention of Influenza

China

3

Subscribe